Search hospitals > Colorado > Denver
The Women's Imaging Center
Claim this profileDenver, Colorado 80209
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Leukemia
96 reported clinical trials
2 medical researchers
Summary
The Women's Imaging Center is a medical facility located in Denver, Colorado. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Leukemia and other specialties. The Women's Imaging Center is involved with conducting 96 clinical trials across 263 conditions. There are 2 research doctors associated with this hospital, such as Nicholas DiBella and Keren Sturtz.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Nicholas DiBellaRocky Mountain Cancer Centers-Boulder5 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
97 reported clinical trials
182 drugs studied
Keren SturtzSCL Health Lutheran Medical Center9 years of reported clinical research
Studies Breast Cancer
Studies Carcinoma
4 reported clinical trials
14 drugs studied
Clinical Trials running at The Women's Imaging Center
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Melanoma
Bladder Cancer
Cancer
Cutaneous Melanoma
Gastroesophageal Junction Adenocarcinoma
Gastric Cancer
Ovarian Cancer
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Mobile Health
for Breast Cancer
This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to enhanced usual care (EUC), where patients only use the WiseBag, to monitor medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor. To ensure CDK4/6 inhibitors achieve their full clinical benefit, patients need to take them as prescribed, following a complex treatment schedule. Forgetfulness was the most common reason reported for medication non adherence. Using the WiseBag along with CONCURxP or enhanced usual care may improve medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor.
Recruiting1 award N/A10 criteria
Cognitive Training
for Breast Cancer Survivors
This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors.
Recruiting1 award N/A5 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at The Women's Imaging Center?
The Women's Imaging Center is a medical facility located in Denver, Colorado. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Leukemia and other specialties. The Women's Imaging Center is involved with conducting 96 clinical trials across 263 conditions. There are 2 research doctors associated with this hospital, such as Nicholas DiBella and Keren Sturtz.